Brief: Abbisko Cayman Says Csf-1R Inhibitor, Pimicotinib (Absk021) Approved By Nmpa For Phase Ii Clinical Study
17/01/2023 24:08
Jan 17 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* CSF-1R INHIBITOR, PIMICOTINIB (ABSK021) APPROVED BY
CHINA'S NMPA
FOR A PHASE II CLINICAL STUDY
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration